Sam Possemiers, MRM Health CEO

MRM open to part­ner­ships af­ter lead can­di­date im­press­es in PhI­Ia ul­cer­a­tive col­i­tis tri­al

MRM Health’s mi­cro­bio­me con­sor­tium ther­a­py for ul­cer­a­tive col­i­tis has shown promise in a Phase IIa tri­al, trig­ger­ing plans for late-stage de­vel­op­ment and po­ten­tial part­ner­ships.

The Bel­gian biotech’s study set the treat­ment, dubbed MH002, against place­bo in 45 peo­ple with mild-to-mod­er­ate UC.

MH002 pro­duced a 12% im­prove­ment in the Mayo En­do­scop­ic Sever­i­ty score, while the score wors­ened by 5% with place­bo (p=0.05). The treat­ment al­so hit sig­nif­i­cance in the end­point of stool con­sis­ten­cy im­prove­ment af­ter two weeks (p=0.006).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.